Table of Contents
ISRN Cardiology
Volume 2013, Article ID 518968, 7 pages
http://dx.doi.org/10.1155/2013/518968
Clinical Study

Dual Antiplatelet Therapy Can Be Discontinued at Three Months after Implantation of Zotarolimus-Eluting Stent in Patients with Coronary Artery Disease

1Department of Cardiology, Fukuyama City Hospital, 5-23-1 Zaou-chou, Fukuyama, Hiroshima 721-8511, Japan
2Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, Japan

Received 1 February 2013; Accepted 12 March 2013

Academic Editors: A. Becker, H. Nathoe, and C. Vassalle

Copyright © 2013 Tadashi Wada et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. B. King III, S. C. Smith Jr., J. W. Hirshfeld Jr. et al., “2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association task force on practice guidelines,” Circulation, vol. 117, no. 2, pp. 261–295, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. J. W. Moses, M. B. Leon, J. J. Popma et al., “Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery,” The New England Journal of Medicine, vol. 349, no. 14, pp. 1315–1323, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. G. W. Stone, S. G. Ellis, D. A. Cox et al., “A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease,” The New England Journal of Medicine, vol. 350, no. 3, pp. 221–231, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. E. L. Eisenstein, K. J. Anstrom, D. F. Kong et al., “Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation,” Journal of the American Medical Association, vol. 297, no. 2, pp. 159–168, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Fajadet, W. Wijns, G. J. Laarman et al., “Randomized, double-blind, multicenter study of the endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial,” Circulation, vol. 114, no. 8, pp. 798–806, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Pfisterer, H. P. Brunner-La Rocca, P. T. Buser et al., “Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents,” Journal of the American College of Cardiology, vol. 48, no. 12, pp. 2584–2591, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. F. Airoldi, A. Colombo, N. Morici et al., “Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment,” Circulation, vol. 116, no. 7, pp. 745–754, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. J. Daemen, P. Wenaweser, K. Tsuchida et al., “Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study,” The Lancet, vol. 369, no. 9562, pp. 667–678, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. H. Hao, H. Ishibashi-Ueda, M. Tsujimoto et al., “Drug-eluting stent-importance of clinico-pathological correlations,” Circulation Journal, vol. 75, no. 7, pp. 1548–1558, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. J. Hallas, M. Dall, A. Andries et al., “Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study,” British Medical Journal, vol. 333, no. 7571, pp. 726–728, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Yusuf, F. Zhao, S. R. Mehta, S. Chrolavicius, G. Tognoni, and K. K. Fox, “Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation,” The New England Journal of Medicine, vol. 345, no. 7, pp. 494–502, 2001. View at Publisher · View at Google Scholar · View at Scopus
  12. Y. Iwata, Y. Kobayashi, K. Fukushima et al., “Incidence of premature discontinuation of antiplatelet therapy after sirolimus-eluting stent implantation,” Circulation Journal, vol. 72, no. 2, pp. 340–341, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. G. Nakazawa, A. V. Finn, M. C. John, F. D. Kolodgie, and R. Virmani, “The significance of preclinical evaluation of sirolimus-, paclitaxel-, and zotarolimus-eluting stents,” American Journal of Cardiology, vol. 100, no. 8, pp. 36M–44M, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. D. M. Whelan, W. J. van der Giessen, S. C. Krabbendam et al., “Biocompatibility of phosphorylcholine coated stents in normal porcine coronary arteries,” Heart, vol. 83, no. 3, pp. 338–345, 2000. View at Google Scholar · View at Scopus
  15. J. W. Kim, H. S. Seo, J. H. Park et al., “A prospective, randomized, 6-month comparison of the coronary vasomotor response associated with a zotarolimus- versus a sirolimus-eluting stent: differential recovery of coronary endothelial dysfunction,” Journal of the American College of Cardiology, vol. 53, no. 18, pp. 1653–1659, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. L. Mauri, J. M. Massaro, S. Jiang et al., “Long-term clinical outcomes with zotarolimus-eluting versus bare-metal coronary stents,” Journal of the American College of Cardiology, vol. 3, no. 12, pp. 1240–1249, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. M. B. Leon, L. Mauri, J. J. Popma et al., “A randomized comparison of the ENDEAVOR zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions 12-month outcomes from the ENDEAVOR IV trial,” Journal of the American College of Cardiology, vol. 55, no. 6, pp. 543–554, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. D. E. Cutlip, S. Windecker, R. Mehran et al., “Clinical end points in coronary stent trials: a case for standardized definitions,” Circulation, vol. 115, no. 17, pp. 2344–2351, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. S. R. Mehta, S. Yusuf, R. J. G. Peters et al., “Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study,” The Lancet, vol. 358, no. 9281, pp. 527–533, 2001. View at Publisher · View at Google Scholar · View at Scopus
  20. D. L. Bhatt, K. A. A. Fox, W. Hacke et al., “Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events,” The New England Journal of Medicine, vol. 354, no. 16, pp. 1706–1717, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. S. R. Steinhubl, P. B. Berger, J. T. Mann III et al., “Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial,” Journal of the American Medical Association, vol. 288, no. 19, pp. 2411–2420, 2002. View at Publisher · View at Google Scholar · View at Scopus
  22. T. Kimura, T. Morimoto, Y. Nakagawa et al., “Antiplatelet therapy and stent thrombosis after sirolimus-eluting stent implantation,” Circulation, vol. 119, no. 7, pp. 987–995, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. R. G. Hart, S. B. Tonarelli, and L. A. Pearce, “Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas,” Stroke, vol. 36, no. 7, pp. 1588–1593, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. K. Toyoda, M. Yasaka, K. Iwade et al., “Dual antithrombotic therapy increases severe bleeding events in patients with stroke and cardiovascular disease: a prospective, multicenter, observational study,” Stroke, vol. 39, no. 6, pp. 1740–1745, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. C. Y. Andrew, G. Armstrong, I. Zeng, and M. W. I. Webster, “Noncardiac surgery and bleeding after percutaneous coronary intervention,” Circulation, vol. 2, no. 3, pp. 213–221, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. D. E. Kandzari, D. J. Angiolillo, M. J. Price, and P. S. Teirstein, “Identifying the, “optimal” duration of dual antiplatelet therapy after drug-eluting stent revascularization,” Journal of the American College of Cardiology, vol. 2, no. 12, pp. 1279–1285, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. J. Y. Hahn, Y. B. Song, J. H. Choi et al., “Three-month dual antiplatelet therapy after implantation of zotarolimus-eluting stents: the DATE (duration of dual antiplatelet therapy after implantation of endeavor stent) registry,” Circulation Journal, vol. 74, no. 11, pp. 2314–2321, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. J. S. Kim, I. K. Jang, C. Fan et al., “Evaluation in 3 months duration of neointimal coverage after zotarolimus-eluting stent implantation by optical coherence tomography: the ENDEAVOR OCT trial,” Journal of the American College of Cardiology, vol. 2, no. 12, pp. 1240–1247, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. J. S. Kim, I. K. Jang, J. S. Kim et al., “Optical coherence tomography evaluation of zotarolimus-eluting stents at 9-month follow-up: comparison with sirolimus-eluting stents,” Heart, vol. 95, no. 23, pp. 1907–1912, 2009. View at Publisher · View at Google Scholar · View at Scopus